

# Yiska Weisblum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6821228/publications.pdf>

Version: 2024-02-01

16  
papers

8,345  
citations

567247

15  
h-index

940516

16  
g-index

29  
all docs

29  
docs citations

29  
times ranked

15013  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. <i>ELife</i> , 2022, 11, .   | 6.0  | 34        |
| 2  | VPS29 Exerts Opposing Effects on Endocytic Viral Entry. <i>MBio</i> , 2022, 13, e0300221.  | 4.1  | 5         |
| 3  | Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1208-e1211. | 5.8  | 65        |
| 4  | Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.  | 27.8 | 1,355     |
| 5  | mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.   | 27.8 | 1,232     |
| 6  | B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.   | 28.9 | 73        |
| 7  | Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.   | 12.8 | 332       |
| 8  | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.  | 14.3 | 230       |
| 9  | High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.  | 27.8 | 174       |
| 10 | Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021, 374, 1099-1106.  | 12.6 | 49        |
| 11 | Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .   | 6.0  | 36        |
| 12 | Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.   | 27.8 | 1,742     |
| 13 | Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .   | 8.5  | 503       |
| 14 | Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .  | 3.9  | 154       |
| 15 | Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.  | 28.9 | 724       |
| 16 | Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .  | 6.0  | 1,239     |